IFLR1000

Valeant Pharmaceutical's $825 million acquisition of Amoun Pharmacuticals

19/10/2015
Public acquisition
Select tab

$ 825 million

Completed

19/10/2015

Overview:

  • Valeant Pharmaceutical acquired Amoun Pharmacuticals for $825 million from Citi Venture Capital, Capital International and Concord International.
  • Concord International is a fund manager groups including Capital, Ethemba, the Rohatyn Group and Concord.
  • Amoun Pharmacuticals is a significant pharmaceutical company in Egypt. 

Rani Mehta - Journalist 

Jurisdictions:

Canada
Egypt

Deal type:

Public acquisition

Practice areas:

Private equity
M&A

Governing law:

Egypt

Industry sector:

Pharmaceuticals and life sciences

Firms:
Baker McKenzie

Party: Citigroup (Seller)

Party: Capital International and Concord International (Seller)

Lawyers: Charles Whitefoord, Mohamed Ghannam

Helmy Hamza & Partners

Party: Citigroup (Seller)

Party: Capital International and Concord International (Seller)

Lawyers: Mohamed Ghannam, Mohamed Ghannam

Matouk Bassiouny

Party: Valeant Pharmaceuticals (Acquirer)

Lawyer: Omar S Bassiouny

Skadden Arps Slate Meagher & Flom

Party: Valeant Pharmaceuticals (Acquirer)

Lawyer: Marie Gibson

Related deals